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25 and the SF-36. Psychometric analyses of baseline data exam-
ined internal consistency (Cronbach’s alpha), criterion validity
(Spearman correlations), and discriminant validity of the VFQ-
25. RESULTS: The 684 enrolled patients were primarily Cau-
casian (77.8%) and male (63.3%), with a mean age of 59.3
years. Cronbach’s alphas for VFQ-25 scales indicated good inter-
nal consistency, ranging from 0.72 to 0.93 for all subscales
except two 2-item subscales, which had alphas of 0.68 (ocular
pain) and 0.64 (social functioning). The VFQ-25 demonstrated
convergent validity through statistically signiﬁcant correlations
with SF-36 subscales. For example, correlations of the VFQ-25
role difﬁculties subscale with the eight SF-36 subscales ranged
from 0.25 to 0.35 (all p < 0.0001). VFQ-25 subscales signiﬁcant
discriminated among groups of patients differing in ETDRS
visual acuity scores (e.g., total VFQ-25 score = 79.1 for patients
with ETDRS score of 48–78 letters; 83.0 for patients with 79–84
letters; 89.0 for patients with 85–100 letters). CONCLUSION:
The VFQ-25 demonstrated adequate internal consistency relia-
bility, criterion validity, and discriminant validity. Results
support the use of this instrument among patients with diabetic
retinopathy.
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OBJECTIVES: Intensive treatment to achieve targeted glycemic
index(HbA1c <7% and FBG <140 mg%) with the help of early
initiation of basal insulin secretion in addition to oral hypo-
glycemic agents has been proposed for type 2 diabetes mellitus.
Insulin glargine has been reported to be as efﬁcacious as NPH
insulin along with oral hypoglycemic agents in type 2 diabetes
mellitus. However, its impact on quality of life has not been eval-
uated. METHODS: Forty patients of type 2 diabetes mellitus on
two or more oral hypoglycemic agents for more than three
months and unable to achieve targeted glycemic index were
enrolled and randomized in a open label comparative trial into
two groups, 20 patient each, taking either insulin glargine or
NPH insulin in combination to previous treatment. The end
points evaluated were glycemic index, hypoglycemic episodes
impact on treatment satisfaction, well being and quality of life.
RESULTS: Both the treatment groups equally achieved eug-
lycemic levels. The mean decrease in HbA1c levels in both groups
was the same but more number of patients (15 vs. 10) were able
to achieve fair to good glycemic control in Insulin glargine group.
Total episodes of hypoglycemia were 50% lesser in insulin
glargine group (13 vs. 26) with no severe and lesser nocturnal
episodes. Quality of life parameters improved in both groups but
were signiﬁcantly higher in insulin glargine group (treatment sat-
isfaction: 43.75 ± 2.05 vs. 34.44 ± 1.68; General well being: 27.1
± 2.37 vs. 16.75 ± 1.58; Total satisfaction: 35.50 ± 2.25 vs. 23.81
± 1.92). Higher number of people had overall good to excellent
rating of quality of life (18 vs. 10). CONCLUSION: Achieve-
ment of target glycemic control was similar in both insulin reg-
imens however; patients on insulin glargine had signiﬁcantly
lesser number of hypoglycemic episodes and far better treatment
satisfaction, Sense of well being and quality of life.
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OBJECTIVES: Hypoglycemia presents a challenge for patients
using insulin. The fear and anxiety related to hypoglycemic
episodes may inhibit intensiﬁed insulin treatment and cause
patients to reduce driving, limit social activities and eat snacks.
However, published estimates of health-related quality of life
values (utilities) for hypoglycemia have been based on database
studies and not directly measured in interviews. Our objective
was to elicit societal and patient utilities in Canada for ﬁve 
health states including: diabetes, rare (quarterly), intermittent
(monthly), frequent (weekly), and nocturnal hypoglycemia
episodes. METHODS: The health state descriptions were based
on the validated Hypoglycemia Fear Survey and the opinions of
four experts. Time trade-off (TTO) interviews were used to elicit
utilities from 79 non-diabetic and 50 diabetic respondents in
Canada. The TTO method estimates utilities between 0 and 1,
where 1 expresses full health and 0 represents dead. Interview-
ers used a TTO board that allowed respondents to trade between
zero and 30 years of perfect health against 30 years in each
health state. RESULTS: The diabetes health state was estimated
at 0.92 (SD 0.13) and 0.88 (SD 0.13) by diabetics and non-dia-
betics, respectively. The disutility was greater with increasing
hypoglycemia: rare episodes ranged from −0.01 to −0.03 in the
two groups; intermittent −0.05 to −0.11; frequent −0.17 to 
−0.22; and nocturnal −0.12 to −0.17. In both groups, the disu-
tility of nocturnal hypoglycemia was intermediate between inter-
mittent and frequent rates hypoglycemia. CONCLUSION: Rare
hypoglycemia episodes occurring only a few times a year, was
rated as having only a minimal impact, whereas frequent
episodes and nocturnal hypoglycemia had substantial impacts.
This study is the ﬁrst to directly estimate utilities for hypo-
glycemia, incorporating appropriately developed health states,
using direct elicitation techniques, and including diabetic and
non-diabetic respondents.
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OBJECTIVES: This study reports differences in utility scores
obtained using the U.S. and U.K. valuations of the EQ-5D in a
cross-sectional study among patients with type 2 diabetes melli-
tus (T2DM). METHODS: Patients with T2DM at the outpatient
clinics of a university hospital completed the EQ-5D. Health
state preference scores were obtained using both the US and UK
valuation systems of the EQ-5D, and matched with retrospective
data including A1C, co-morbidities, diabetes-related complica-
tions, and BMI from electronic records and with self-report of
insulin use and depressive symptoms (using the Center for Epi-
demiologic Studies—Depression). Paired sample t-tests assessed
overall differences in US and UK scores. Using EQ-5D scores as
the dependent variable, OLS regressions assessed the signiﬁcance
of diabetes-related complications and co-morbidities as predic-
tors (dichotomized) individually; these were also preformed
using US-UK difference scores as the dependent variable.
